Abstract
In normal healthy tissues, an equilibrium is established between cell death and survival. This equilibrium ensures that cells survive in the right milieu, but undergo programmed cell death (apoptosis) when damaged, or when the environment is no longer supportive. Diseases may occur with alterations in this homeostasis. For example, cancer cells may survive in an environment in which they would not normally exist. This is accomplished by alterations in the expressions or functions of genes controlling both survival and apoptotic signaling pathways. Survival signaling pathways involve the activation of cell surface receptors, serine threonine kinases, transcription factors as well as other molecules. In breast and ovarian cancers, the ErbB2 growth factor receptor is overexpressed and this contributes to the progression of these cancers, in part by constitutively activating survival signaling pathways. In contrast, apoptotic signal transduction pathways are often inhibited in cancer. For example, overexpression of Bcl-2 blocks apoptosis and this contributes to the accumulation of cells in follicular lymphomas and chronic lymphocytic leukemia. Furthermore, alterations in these signaling pathways in cancer cells may lead to drug resistance. Recent advances in molecular targeted therapies have taken advantage of alterations in survival and apoptotic signaling pathways in cancer to specifically target aberrantly regulated molecules. For example, Herceptin inhibits ErbB2 function and antisense oligonucleotides against Bcl-2 reduce Bcl-2 expression. These agents can thus induce apoptosis in the specific cancer cell against which they have been targeted. In this review, we will discuss alteration in survival and apoptotic signal transduction pathways in cancer and the development of novel chemotherapeutic drugs to target these pathways.
Current Cancer Drug Targets
Title: Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Volume: 4 Issue: 2
Author(s): Albert F. Kabore, James B. Johnston and Spencer B. Gibson
Affiliation:
Keywords: lymphomas, Herceptin, apoptosis
Abstract: In normal healthy tissues, an equilibrium is established between cell death and survival. This equilibrium ensures that cells survive in the right milieu, but undergo programmed cell death (apoptosis) when damaged, or when the environment is no longer supportive. Diseases may occur with alterations in this homeostasis. For example, cancer cells may survive in an environment in which they would not normally exist. This is accomplished by alterations in the expressions or functions of genes controlling both survival and apoptotic signaling pathways. Survival signaling pathways involve the activation of cell surface receptors, serine threonine kinases, transcription factors as well as other molecules. In breast and ovarian cancers, the ErbB2 growth factor receptor is overexpressed and this contributes to the progression of these cancers, in part by constitutively activating survival signaling pathways. In contrast, apoptotic signal transduction pathways are often inhibited in cancer. For example, overexpression of Bcl-2 blocks apoptosis and this contributes to the accumulation of cells in follicular lymphomas and chronic lymphocytic leukemia. Furthermore, alterations in these signaling pathways in cancer cells may lead to drug resistance. Recent advances in molecular targeted therapies have taken advantage of alterations in survival and apoptotic signaling pathways in cancer to specifically target aberrantly regulated molecules. For example, Herceptin inhibits ErbB2 function and antisense oligonucleotides against Bcl-2 reduce Bcl-2 expression. These agents can thus induce apoptosis in the specific cancer cell against which they have been targeted. In this review, we will discuss alteration in survival and apoptotic signal transduction pathways in cancer and the development of novel chemotherapeutic drugs to target these pathways.
Export Options
About this article
Cite this article as:
Kabore F. Albert, Johnston B. James and Gibson B. Spencer, Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications, Current Cancer Drug Targets 2004; 4 (2) . https://dx.doi.org/10.2174/1568009043481551
DOI https://dx.doi.org/10.2174/1568009043481551 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
6-Bromo-2,3-Dioxoindolin Phenylacetamide Derivatives: Synthesis, Potent CDC25B, PTP1B Inhibitors and Anticancer Activity
Letters in Drug Design & Discovery Chartreusin, Elsamicin A and Related Anti-Cancer Antibiotics
Current Medicinal Chemistry - Anti-Cancer Agents Naturally Occuring Pyrrolo[1,4]benzodiazepines in Bacteria
Mini-Reviews in Organic Chemistry Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Ovarian Toxicity: From Environmental Exposure to Chemotherapy
Current Pharmaceutical Design Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Natural Bioactive Compounds as Emerging Therapeutic Molecules Against Breast Cancer: Emphasis on the Role of Phytoestrogens
Current Drug Targets Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery The Antitumor Effects of Icaritin Against Breast Cancer is Related to Estrogen Receptors
Current Molecular Medicine Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets New Generation of Liposomes Called Archaeosomes Based on Natural or Synthetic Archaeal Lipids as Innovative Formulations for Drug Delivery
Recent Patents on Drug Delivery & Formulation Efficacy and Safety of Sleeping Beauty Transposon-Mediated Gene Transfer in Preclinical Animal Studies
Current Gene Therapy Role of microRNA Deregulation in Breast Cancer Cell Chemoresistance and Stemness
Current Medicinal Chemistry Mesenchymal Stromal Cells; Role in Tissue Repair, Drug Discovery and Immune Modulation
Current Drug Delivery Advances in the Use of Multifunctional Mesoporous Silica Nanoparticles and Related Nanomaterials as Carriers for the Cancer Treatment
Current Drug Metabolism In Vivo Models of Childhood Leukemia for Preclinical Drug Testing
Current Drug Targets